Inhibrx Stock Odds of Future Stock Price Finishing Under 7.35

INBX Stock  USD 14.94  0.45  3.11%   
Inhibrx's future price is the expected price of Inhibrx instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Inhibrx performance during a given time horizon utilizing its historical volatility. Check out Inhibrx Backtesting, Inhibrx Valuation, Inhibrx Correlation, Inhibrx Hype Analysis, Inhibrx Volatility, Inhibrx History as well as Inhibrx Performance.
For more information on how to buy Inhibrx Stock please use our How to Invest in Inhibrx guide.
  
At this time, Inhibrx's Price To Sales Ratio is fairly stable compared to the past year. Price Book Value Ratio is likely to rise to 43.23 in 2024, whereas Price Earnings Ratio is likely to drop (7.79) in 2024. Please specify Inhibrx's target price for which you would like Inhibrx odds to be computed.

Inhibrx Target Price Odds to finish below 7.35

The tendency of Inhibrx Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to drop to $ 7.35  or more in 90 days
 14.94 90 days 7.35 
near 1
Based on a normal probability distribution, the odds of Inhibrx to drop to $ 7.35  or more in 90 days from now is near 1 (This Inhibrx probability density function shows the probability of Inhibrx Stock to fall within a particular range of prices over 90 days) . Probability of Inhibrx price to stay between $ 7.35  and its current price of $14.94 at the end of the 90-day period is about 32.85 .
Given the investment horizon of 90 days Inhibrx has a beta of 0.39. This usually indicates as returns on the market go up, Inhibrx average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Inhibrx will be expected to be much smaller as well. Additionally Inhibrx has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Inhibrx Price Density   
       Price  

Predictive Modules for Inhibrx

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Inhibrx. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
12.3114.8817.45
Details
Intrinsic
Valuation
LowRealHigh
13.4122.8925.46
Details
0 Analysts
Consensus
LowTargetHigh
42.5446.7551.89
Details
Earnings
Estimates (0)
LowProjected EPSHigh
21.8825.5129.14
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Inhibrx. Your research has to be compared to or analyzed against Inhibrx's peers to derive any actionable benefits. When done correctly, Inhibrx's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Inhibrx.

Inhibrx Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Inhibrx is not an exception. The market had few large corrections towards the Inhibrx's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Inhibrx, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Inhibrx within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.05
β
Beta against Dow Jones0.39
σ
Overall volatility
0.70
Ir
Information ratio -0.03

Inhibrx Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Inhibrx for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Inhibrx can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Inhibrx generated a negative expected return over the last 90 days
Inhibrx has a very high chance of going through financial distress in the upcoming years
Inhibrx was previously known as INXB Old and was traded on NASDAQ Exchange under the symbol INXB.
The company reported the previous year's revenue of 1.8 M. Net Loss for the year was (241.36 M) with loss before overhead, payroll, taxes, and interest of (107.99 M).
Inhibrx currently holds about 176.38 M in cash with (193.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.52.
Inhibrx has a frail financial position based on the latest SEC disclosures
Roughly 67.0% of the company shares are owned by institutional investors
Latest headline from investing.com: Inhibrxs SWOT analysis biotech stock faces pivotal year amid clinical trials

Inhibrx Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Inhibrx Stock often depends not only on the future outlook of the current and potential Inhibrx's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Inhibrx's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding47.1 M
Cash And Short Term Investments277.9 M

Inhibrx Technical Analysis

Inhibrx's future price can be derived by breaking down and analyzing its technical indicators over time. Inhibrx Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Inhibrx. In general, you should focus on analyzing Inhibrx Stock price patterns and their correlations with different microeconomic environments and drivers.

Inhibrx Predictive Forecast Models

Inhibrx's time-series forecasting models is one of many Inhibrx's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Inhibrx's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Inhibrx

Checking the ongoing alerts about Inhibrx for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Inhibrx help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Inhibrx generated a negative expected return over the last 90 days
Inhibrx has a very high chance of going through financial distress in the upcoming years
Inhibrx was previously known as INXB Old and was traded on NASDAQ Exchange under the symbol INXB.
The company reported the previous year's revenue of 1.8 M. Net Loss for the year was (241.36 M) with loss before overhead, payroll, taxes, and interest of (107.99 M).
Inhibrx currently holds about 176.38 M in cash with (193.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.52.
Inhibrx has a frail financial position based on the latest SEC disclosures
Roughly 67.0% of the company shares are owned by institutional investors
Latest headline from investing.com: Inhibrxs SWOT analysis biotech stock faces pivotal year amid clinical trials

Additional Tools for Inhibrx Stock Analysis

When running Inhibrx's price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.